Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
Condition: Helminthiasis
MeSH terms: Helminthiasis
Intervention: Albendazole
Intervention description: Albendazole tablets 400 mg
Intervention MeSH terms: Albendazole
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 56.0
Sex: Male
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of the study is to compare the pharmacokinetic profiles of two Albendazole tablet
      formulations manufactured under the different granulation processes in healthy Chinese adult
      males.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male aged from 18 years up to 40 years (inclusive).

          2. Body mass index within the range of 19-24kg/m^2.

          3. Good general health with (in the opinion of the investigator) no clinically
             significant and relevant abnormalities of medical history or physical examination.

          4. Negative for serum hepatitis B surface antigen, hepatitis C antibody and antibody of
             HIV.

        Exclusion Criteria:

          1. Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study
             materials (or closely related compounds) or any of their stated ingredients.

          2. Substance abuse: Recent history (within the last year) of alcohol or other substance
             abuse or failed to pass drugs of abuse screen and/or alcohol screen test.

          3. Disease

               1. Current or recurrent disease that could affect the action, absorption or
                  distribution of the study medication or clinical or laboratory assessments (e.g.
                  hepatic disorders, abnormal liver function tests, renal insufficiency, congestive
                  heart failure);

               2. Current or relevant previous history of serious, severe or unstable physical or
                  psychiatric illness, any medical disorder that may require treatment or make the
                  subject unlikely to fully complete the study, or any condition that presents
                  undue risk from the study medication or procedures;

               3. History of gastrointestinal bleeding or peptic ulcer;

               4. Asthma

               5. History of liver disease

          4. Medication

               1. Use of any drug known to induce or inhibit hepatic drug metabolism in the 30 days
                  prior to dosing

               2. Current or regular use of any prescription or over-the-counter medication, any
                  other ABZ containing products, and traditional Chinese medicine.

          5. Smoking

               1. Subjects who are current smokers or non-smokers of less than 3 months;

               2. Prior (within seven days of dosing) or current use of any other nicotine
                  containing products, including nicotine replacement therapy.

          6. Blood

               1. Blood donation ≥ 500 ml within 90 days before the first study session.

               2. Plasma donation within the 90 days before the first study session.